Abstract: A set of target peptides are presented by HLA A*0101, A*0201, A*0301, B*4402, B*2705, B*1402, and B*0702 on the surface of disease cells. They are envisioned to among other things (a) stimulate an immune response to the proliferative disease, e.g., cancer, (b) to function as immunotherapeutics in adoptive T cell therapy or as a vaccine, (c) facilitate antibody recognition of tumor boundaries in surgical pathology samples, (d) act as biomarkers for early detection and/or diagnosis of the disease, and (e) act as targets in the generation antibody-like molecules which recognize the target-peptide/MHC complex.

Abstract: Existing feedstock for additive manufacturing is mostly stiff, fragile plastics. We report a class of 3D printable, ultrasoft and stretchable elastomers by exploiting the self-assembly of responsive bottlebrush-based triblock copolymers. The microphase separation of the architecturally and chemically distinct blocks results in physically crosslinked networks that are stimuli-reversible, enabling their use for in-situ direct-write printing soft, elastic, and deformable 3D structures. The elastomers are 100% solvent-reprocessable yet thermostable within a wide range of temperature. Moreover, they exhibit an extensibility up to 600% and a Young's modulus low to ˜102 Pa, 106 times softer than plastics and more than 100 times softer than all existing 3D printable elastomers.

Abstract: Sulfonyl-triazole compounds and related sulfonyl-heterocycle compounds are described. Exemplary compounds can form covalent adducts with reactive nucleophilic amino acid residues in proteins, such as reactive tyrosines, to form modified proteins and/or to alter the biological activity of the proteins. Pharmaceutical compositions comprising the compounds and methods of inhibiting prostaglandin reductase 2 (PTGR2) are also described. In addition, methods are described for screening proteins to identify druggable amino acid residues, e.g., druggable tyrosine and/or lysine residues.

Abstract: Provided are antibodies that include amino acid sequences of SEQ ID NOs: 2, 4, 6, 14, 16, or 18, or amino acid sequences that are about 95% identical thereto, and paratop-containing fragments thereof. Also provided are nucleic acids encoding a VII segment comprising, consisting essentially of, or consisting of SEQ ID NO: 4, a VL segment comprising, consisting essentially of, or consisting of SEQ ID NO: 16, or a combination thereof: methods for using the same to detect and/or target conformational states of FN in samples: methods for treating diseases and/or disorders and/or for meliorating at least one symptom of consequence of a disease or disorder associated with abnormal expression of a force-induced conformational state of FN in subjects: and methods for screening for compounds having selective binding activities for conformational states of FN.

Abstract: A surgical incision apparatus and method for puncturing a cutaneous layer of a subject for providing guided access to a subcutaneous organ or subcutaneous cavity (or specified target region) of the subject. The apparatus may include a retention body configured for securing a cutting tool therein and a housing configured for receiving the retention body. The apparatus includes a guidewire holder member configured for receiving a guidewire therein and aligning with the guidewire to allow the cutting tool to travel along the guidewire. The retention body is configured to be movably attached relative to the housing to allow the retention body and cutting tool to advance toward the subject to a deployed position, and subsequently withdraw to a retracted position.

Abstract: A method and system for generating pulse oximetry predictive scores (POPS) for predicting adverse outcomes in preterm infants. The method comprising generating a POPS via a predictive algorithm which incorporates cross-correlation of heart rate and SpO2 calculated on archived pulse oximetry data of multiple preterm infants, and predicting a pathology of a preterm infant based on the generated POPS, wherein the pathology is intraventricular hemorrhage, late-onset sepsis, necrotizing enterocolitis, bronchopulmonary dysplasia, or retinopathy of prematurity, and informing a user of an opportunity to: identify the preterm infant as a highest risk infant and perform additional surveillance of or therapeutic intervention on the preterm infant, identify the preterm infant for participation in a clinical trial based on a risk profile associated with the POPS, and treat said preterm infant for the pathology.

Abstract: The present disclosure provides soluble truncated mutant programmed death-ligand 1 (PD-L1) peptides. Polynucleotides and vectors encoding the soluble truncated mutant PD-L1 peptides are also provided. Further, methods of using the soluble truncated mutant peptides to promote differentiation of CD4+ effector T (Th1) cells into Foxp3+ regulatory T (Treg) cells are provided.

Abstract: Injectable fibrous hydrogel are provided. The injectable fibrous hydrogels include a guest macromer of a hyaluronic acid (HA) backbone and host macromer of a HA backbone, the guest macromer is a HA electrospun hydrogel nanofiber functionalized with adamantane (Ad), and the host macromer is a HA electrospun hydrogel nanofiber functionalized with ?-cyclodextrin (CD). Injectable formulations that include the fibrous hydrogels are also provided, as are methods of making and using the same.

Abstract: Microfluidic devices for analyzing cellular components from biological samples which contain more than one cell type are provided. The microdevice separates cells by type, releases cellular components such as DNA (e.g. by cell lysis) and processes the cellular components (for example, by amplification) to generate products of interest for further analysis. Samples that can be analyzed using the microfluidic devices include forensic samples such as samples from sexual assault victims, and the products of interest include short tandem repeat (STR) amplicons for DNA profiling.

Abstract: Provided are isolated TCRs, TCR-like molecules, and portions thereof that bind to phosphopeptide-HLA-A2 complexes. The isolated TCRs, TCR-like molecules, or portions are optionally soluble TCRs, TCR-like molecules, or portions. Also provided are isolated nucleic acids encoding the disclosed TCRs, TCR-like molecules, or portions; host cells that contain the disclosed TCRs, TCR-like molecules, or portions; pharmaceutical compositions that include the disclosed TCRs, TCR-like molecules, portions, nucleic acids, and/or T cells; kits; and methods of using the same.

Abstract: Disclosed are phototunable hydrogels, compositions that include the same, and methods for using the same for treating wounds and/or injuries, for inhibiting formation of scar tissue at wound sites, for inhibiting fibrosis in subjects in need thereof, for inhibiting lung fibrosis and/or scarring in subject in need thereof, for inhibiting formation of myofibroblasts from fibroblasts, and for inhibiting expression of ?-smooth muscle actin (?-SMA) and/or type I collagen in fibroblasts.

Abstract: The spinal cord stimulation device of this invention is configured for implantation into a patient so as to traverse the dura mater that surrounds the spinal cord. Placing the device in this location provides direct contact between the electrode and the cerebrospinal fluid (CSF), in close proximity to the spinal cord. The device has an intradural portion and an extradural portion that compresses and seals the dural membrane between them, securing the device in position and preventing leakage of CSF. The position of the device may be stabilized in relation to the spinal cord by way of a laminoplasty plate, bridging between the device and a vertebra. The device is electronically powered by an implanted pulse generator that produces a spectrum of signals to interrupt or otherwise attenuate transmission of pain mediating neural signals through the spinal cord.

Abstract: Provided are methods for treating and/or preventing genotoxic stress-induced cardiac toxicity, which in some embodiments include administering to a subject an effective amount of an inhibitor of t-CH, of neutrophil activation, of neutrophil migration, or any combination thereof. In some embodiments, the genotoxic stress-induced cardiac toxicity results from exposure to one or more anti-tumor and/or anti-cancer therapies, including but not limited to treatment with one or more chemotherapeutics (e.g., doxorubicin) and/or treatment with radiation. In some embodiments, the genotoxic stress-induced cardiac toxicity, the chemotherapy-induced cardiac toxicity, the chemotherapy-induced heart damage, and/or the chemotherapy-induced reduction in cardiac function is characterized by a reduction in cardiac contractility, a thinning of a ventricular wall, a reduction in cardiomyocyte size, or any combination thereof.

Abstract: The present disclosure relates to systems and methods that provide a reconfigurable cryptographic coprocessor. An example system includes an instruction memory configured to provide ARX instructions and mode control instructions. The system also includes an adjustable-width arithmetic logic unit, an adjustable-width rotator, and a coefficient memory. A bit width of the adjustable-width arithmetic logic unit and a bit width of the adjustable-width rotator are adjusted according to the mode control instructions. The coefficient memory is configured to provide variable-width words to the arithmetic logic unit and the rotator. The arithmetic logic unit and the rotator are configured to carry out the ARX instructions on the provided variable-width words. The systems and methods described herein could accelerate various applications, such as deep learning, by assigning one or more of the disclosed reconfigurable coprocessors to work as a central computation unit in a neural network.

Abstract: Some embodiments relate to imageable radioisotopic microspheres. In some embodiments, the imageable microspheres are radiolabeled with imageable radioisotopes. In some embodiments, the imageable radioisotope is directly coupled to a surface of a substrate of the microsphere. In some embodiments, the imageable microspheres can be used as surrogate particles to predict the distribution of therapeutic microspheres comprising radiotherapeutic isotopes.

Abstract: An exemplary method and system is disclosed that facilitate the integration of multiplexed single-cell impedance cytometry in a high throughput format, which can be deployed upstream from microfluidic sample preparation and/or downstream to microfluidic cell separation. In exemplary method and system may employ impedance-based quantification of cell electrophysiology on the same microfluidic chip (i.e., “on-chip”) to provide distinguishing phenotypic information on the sample, without the need for additional sample handling, preparation or dilution steps as would be needed for other flow cytometry techniques.

Abstract: Methods of modeling the in vivo efficacy of drug combinations for the treatment or prevention of viral infection are described. The described methods combine data for single drugs and drug combinations from pharmacokinetic, pharmacodynamic, and viral dynamics models under a series of estimated in vivo drug potencies to provide predictions of the in vivo effects of the drug combinations. These predictions can be used to more accurately select drugs and drug treatment regimens that can be successful in controlling viral infection in animal studies, clinical trials and in medical or veterinary interventions. Also described is a method of treating or preventing filovirus infections using combinations of orally available drugs based on predictions from the modeling methods.

Abstract: Compositions and methods are provided that are useful for diagnosing, treating, and monitoring alcohol dependence and disorders, susceptibility to alcohol dependence disorders, as well as drug related dependence and disorders. The methods include treating patients with an antagonist of the serotonin receptor 5-HT3 for such disorders, wherein the patient's serotonin transporter gene SLC6A4 is known to have particular genotypes.

Abstract: In one aspect, the disclosure relates to compounds useful to regulate, limit, or inhibit the expression of AVIL (advillin), methods of making same, pharmaceutical compositions comprising same, and methods of treating disorders associated with AVIL dysregulation using same. In aspects, the disclosed compounds, compositions and methods are useful for treating disorders or diseases in which the regulation, limitation, or inhibition of the expression of AVIL can be clinically useful, such as, for example, the treatment of cancer. This abstract is intended as a scanning tool for purposes of searching in the particular art and is not intended to be limiting of the present disclosure.

Abstract: Provided are compositions that include targeting peptides and methods for using the same to treat and/or prevent various diseases, disorders, and/or conditions. In some embodiments, the compositions and methods relate to liposomal compositions that include a liposome, the surface of which is conjugated to a peptide having an amino acid sequence as set forth in any of SEQ ID NOS: 3-38, optionally wherein the liposome encapsulates a therapeutic agent or a detectable agent. In some embodiments, the peptide has an amino acid sequence that is one of SEQ ID NOs: 14, 19, 20, 27, and 28. Also provided are methods treating or preventing fibrosis, for decreasing the incidence of a disease, disorder, or condition associated with chronic pancreatitis (CP), for targeting active agents to targets, including but not limited to collagen III-expressing cells and extracellular matrix, and for decreasing incidence of side effects associated with apigenin treatment.